Results 141 to 150 of about 642,659 (199)

The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism

Scientific Reports
Doxorubicin (DOX) is an anthracycline class of chemotherapy drug, the application of which is limited due to its cardiotoxic effects. Recombinant Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), is a serine protease pivotal in lipid metabolism and ...
Shuai Shi, Zhihui Qin, Chang Liu, Yanru Zhao, Xiaopeng Bai, Chaoyu Sun, Xu Li, Wanting Cong, Xinyue Yuan, Lixiu Sun, Bingchen Liu, Xueqi Li   +11 more
doaj   +1 more source

Combating ageing beyond the cell: Emerging roles of extracellular proteostasis

The FEBS Journal, Volume 293, Issue 18, Page 5558-5584, September 2026.
Ageing challenges the body's ability to maintain a stable and functional proteome, leading to protein damage and aggregation both inside and outside cells. This review focuses on the less well understood mechanisms of extracellular protein quality control and how they become disrupted in ageing, particularly in neurodegenerative diseases.
Siddharth R. Venkatesh, Ivan Gallotta, Bolanle F. Olabiyi, Yoon Hee Choi, Sarah Inglesfield, Janet R. Kumita, Collin Y. Ewald, Della C. David   +7 more
wiley   +1 more source

Guideline for the Comprehensive Perioperative Management of Older Patients With Lung Cancer (2025)

Journal of Evidence-Based Medicine, Volume 19, Issue 3, September 2026.
ABSTRACT With the accelerating population aging, the number of older adult patients with lung cancer continues to increase. These patients often present with multiple chronic diseases and geriatric syndromes, resulting in more complex perioperative management and significantly increased surgical risks.
Daiping Li, Rui Liang, Birong Dong, Lunxu Liu, Ning Ge, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University   +6 more
wiley   +1 more source

Anti‐inflammatory agents in atherosclerosis—and a need for reform: Extraordinary claims require extraordinary evidence

Journal of Internal Medicine, Volume 300, Issue 3, Page 258-283, September 2026.
Abstract Since 1858, human atherosclerotic plaques have been shown to contain immune cells. But are these cells suitable therapeutic targets? Dozens of clinical trials of anti‐inflammatory agents other than colchicine have been performed in patients with clinically evident atherosclerosis.
Kevin Jon Williams
wiley   +1 more source

Cardiovascular benefits of PCSK9 inhibition

PCSK9 is an inhibitor of the receptor that is responsible for removing LDL (the bad cholesterol) from the circulation. We will study the molecular mechanisms that inhibit PCSK9 at the protein level.

core  

Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis. [PDF]

J Cardiovasc Dev Dis
Yagmur B, Cekirdekci EI.
europepmc   +1 more source

Association Between PCSK9 Inhibitor Use and Risk of Age-Related Macular Degeneration. [PDF]

Transl Vis Sci Technol
Tsai CY, Weng CH, Tsai CY, Sheen YJ, Chen JP, Chen HM, Wang IJ, Chou CC.   +7 more
europepmc   +1 more source

Inhibiteurs de PCSK9 : futur traitement pour baisser le cholestérol?

, 2014
The achievement rate of recommended low-density lipoprotein cholesterol (LDL-C) targets of < 1.8 mmol/l for secondary prevention in very high risk patients is difficult.
Mach, F, Rodondi, Nicolas, Gencer, B
core  

PCSK9 Inhibitor Attenuates Platelet TLR4 in ACS and TLR4 Blockers Prevent PCSK9-Mediated Platelet Activation. [PDF]

Acta Cardiol Sin
Qi L, Yuan M, Liu X, Liu T, Zhang Y, Chen K.   +5 more
europepmc   +1 more source

PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study. [PDF]

Eur Heart J
Bhatt DL, Perrone Filardi P, Khan I, Tuñón J, Marx N, Castro Cabezas M, Andrade K, Koumas A, Lou Z, Tokgözoğlu L.   +9 more
europepmc   +1 more source